Specific immunotherapy using encapsulated allergens

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


.


Full Text

Restricted Access

About the authors

E V Svirshchevskaya

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS

Author for correspondence.
Email: info@rusalljournal.ru
Moscow

E I Kashirina

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS

Email: info@rusalljournal.ru
Moscow

D B Chudakov

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS

Email: info@rusalljournal.ru
Moscow

A S Dolgova

Institute of epidemiology of Rospotrebnadzor

Email: info@rusalljournal.ru
Moscow

S V Khlgatian

Mechnikov’s Institute of vaccine and sera

Email: info@rusalljournal.ru
Moscow

References

  1. Jacobsen L, Wahn U, Bilo BM. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012. V. 2. № 1. P. 8.
  2. Yang L, Hirose S, Suzuki K, Hiroi T, Takaiwa F. Expression of hypoallergenic Der f 2 derivatives with altered intramolecular disulphide bonds induces the formation of novel ER-derived protein bodies in transgenic rice seeds. J Exp Bot. 2012. V. 63. № 8. P. 2947.
  3. Bonura A, Passantino R, Costa MA, Montana G, Melis M, Bondi ML, Butteroni C, Barletta B, Corinti S, Di Felice G, Colombo P. Characterization of a Par j 1/Par j 2 mutant hybrid with reduced allergenicity for immunotherapy of Parietaria allergy. Clin Exp Allergy. 2012. V. 42. №. 3. P. 471.
  4. Heydenreich B, Bellinghausen I, Lorenz S, Henmar H, Strand D, Würtzen PA, Saloga J. Reduced in vitro T cell responses induced by glutaraldehyde modified allergen extracts are caused mainly by retarded internalization of dendritic cells. Immunology. 2012. V. 136. № 2. P. 208.
  5. Arca HC, Günbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines. 2009. V. 8. № 7. P. 937.
  6. Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv. 2012. V. 9. № 9. P. 1051.
  7. Li J, Liu Z, Wu Y, Wu H, Ran P. Chitosan microparticles loaded with mite group 2 allergen Der f 2 alleviate asthma in mice. J Investig Allergol Clin Immunol. 2008. V. 18. № 6. P. 454.
  8. Liu Z, Guo H, Wu Y, Yu H, Yang H, Li J. Local nasal immunotherapy: efficacy of Dermatophagoides farinae -chitosan vaccine in murine asthma. Int Arch Allergy Immunol. 2009. V. 150. № 3. P. 221.
  9. Yu HQ, Liu ZG, Guo H, Zhou YP. [Therapeutic effect on murine asthma with sublingual use of Dermatophagoides farinae/chitosan nanoparticle vaccine]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2011. V. 29. № 1. P. 4.

Statistics

Views

Abstract - 49

PDF (Russian) - 0

PlumX

Article Metrics

Metrics Loading ...

Dimensions


Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies